natgillin/translations-raw huggingface dataset:
If used in other domestic and wild ruminant species that are considered at risk of infection, its use in these species should be undertaken with care and it is advisable to test the vaccine on a small number of animals prior to mass vaccination.
Pri drugih domačih in divjih vrstah prežvekovalcev, za katere menimo, da jih ogroža okužba, je treba cepivo uporabiti previdno in ga pred masovnim cepljenjem testirati na majhnem številu živali.
MARKETING AUTHORISATION NUMBER(S) EU/2/10/106/001-014
ŠTEVILKA(E) DOVOLJENJ(A) ZA PROMET EU/2/10./106./001-014
Onset of immunity:
Začetek imunosti:
A. MANUFACTURERS OF THE BIOLOGICAL ACTIVE SUBSTANCE AND MANUFACTURER RESPONSIBLE FOR BATCH RELEASE
A. IZDELOVALCI BIOLOŠKE ZDRAVILNE UČINKOVINE IN IZDELOVALEC, ODGOVOREN ZA SPROSTITEV SERIJE
Incompatibilities: Do not mix with any other veterinary medicinal product.
Inkompatibilnosti Ne mešajte z nobenim drugim zdravilom za uporabo v veterinarski medicini.
Opalescent pink with resuspendable sediment.
Suspenzija za injiciranje Opalescentno roza s sedimentom, ki se resuspendira.
In sheep, these swellings typically last for up to three weeks, while in cattle small palpable swellings may still be present up to six weeks after vaccination in approximately one third of vaccinates.
Pri ovcah traja oteklina do tri tedne, medtem ko lahko pri govedu majhne otekline otipamo do šest tednov po cepljenju pri približno tretjini cepljenih živali.
EXP {month/year} Once broached, use within 8 hours.
Odprto zdravilo uporabite v 8 urah.
Duration of immunity: 6 months.
Trajanje imunosti:
Bluetongue virus serotype 8 (prior to inactivation): 500 antigenic units*.
Virus bolezni modrikastega jezika, serotip 8 (pred inaktivacijo): 500 antigenskih enot*
In sheep, swellings may still be palpable after six weeks.
Pri ovcah so lahko otekline otipljive še po šestih tednih.
In sheep these swellings typically last for up to three weeks.
Pri ovcah traja oteklina do tri tedne.
Any person intending to manufacture, import, possess, sell, supply and use Bovilis BTV8 must consult the relevant Member State's competent authority on the current vaccination policies prior to the manufacture, import, possession, sale, supply and/or use.
Bovilis BTV8, se mora posvetovati s pristojnimi organi posamezne države članice o veljavnih programih cepljenja še pred izdelovanjem, uvozom/vnoson, posedovanjem, prodajo, oskrbo in/ali uporabo.
As the duration of immunity is not yet fully established, any revaccination scheme should be agreed by the Competent Authority or by the responsible veterinarian, taking into account the local epidemiological situation.
Ker trajanje imunosti še ni natančno določeno, mora shemo revakcinacije odobriti pristojni organ ali odgovorni veterinar ob upoštevanju lokalne epidemiološke situacije.
PET vials of 10, 20, 50, 100, 200, 250 or 500 ml, with a rubber stopper and aluminium cap.
Viale iz PET po 10, 20, 50, 100, 200, 250 ali 500 ml z gumijastimi zamaški in aluminijastimi zaporkami
Vials: 100 ml 200 ml 250 ml 500 ml
Viale 100 ml 200 ml 250 ml 500 ml
Do not use this veterinary medicinal product after the expiry date which is stated on the label and carton after EXP.Once broached use within 8 hours, provided the product is not subject to temperatures above 37 °C or contaminated.
Odprto zdravilo uporabite v 8 urah, če zdravilo ni izpostavljen temperaturi nad 37 °C ali kontaminirano.
To stimulate active immunity in cattle from 6 weeks of age against bluetongue virus serotype 8 to reduce viraemia*.
Vzbujanje aktivne imunosti proti serotipu 8 virusa bolezni modrikastega jezika pri govedu od starosti 6 tednov, da zmanjšamo viremijo.
Shelf life of the veterinary medicinal product as packaged for sale for 10, 20, 50 ml vials: 2 years Shelf life of the veterinary medicinal product as packaged for sale for 100, 200, 250, 500 ml vials: 1 year.
Rok uporabnosti zdravila za uporabo v veterinarski medicini v pakiranju za prodajo za viale po 100, 200, 250, 500 ml: 1 leto
No adverse reactions other than those described in section 4.6 were observed following administration of a double dose in cattle and sheep.
Dajanje dvojnega odmerka pri govedu in ovcah ni povzročilo neželenih reakcij, ki bi se razlikovale od reakcij, opisanih v poglavju 4.6.
CLINICAL PARTICULARS
IMUNOLOŠKE LASTNOSTI
STATEMENT OF ACTIVE AND OTHER SUBSTANCES Bluetongue virus serotype 8: 500 antigenic units/ml.
Serotip 8 virusa bolezni modrikastega jezika: 500 antigenskih enot/ml
Cattle from 6 weeks of age: subcutaneous injection of two doses of 1 ml, administered with an interval of approximately 3 weeks.
Govedo od 6 mesecev starosti: dva odmerka po 1 ml subkutano v razmiku približno 3 tednov.
Sheep from 1 month of age: subcutaneous injection of a single dose of 1 ml.
Ovce od starosti 1 meseca: enkratni odmerek po 1 ml subkutano.
Active ingredient: bluetongue virus serotype 8: 500 antigenic units* (* inducing a virus neutralising antibody response in chickens of ≥ 5.0 log2) Adjuvants: aluminium hydroxide, saponin.
Zdravilna učinkovina: serotip 8 virusa bolezni modrikastega jezika: 500 antigenskih enot* (*pri piščancih vzbudi titer protiteles z nevtralizirajočim učinkom na virus ≥ 5,0 log2.)
To be supplied only on veterinary prescription.
Na veterinarski recept
PARTICULARS TO APPEAR ON THE OUTER PACKAGE Cardboard box (10, 20, 50, 100, 200, 250 or 500 ml) PARTICULARS TO APPEAR ON THE IMMEDIATE PACKAGE Vials (100, 200, 250 or 500 ml PET vials)
Kartonska škatla (10, 20, 50, 100, 200, 250 ali 500 ml)
The vaccine is presented in cardboard boxes with 1 or 10 PET vials containing 10, 20, 50, 100, 200, 250 or 500 ml, closed with a rubber stopper and aluminium cap.
Cepivo je pakirano v kartonske škatle z 1 ali 10 vialami iz PET po 10, 20, 50, 100, 200, 250 ali
TARGET SPECIES Cattle and sheep
Goveda in ovce
Veterinary medicinal product subject to prescription.
IME ZDRAVILA ZA UPORABO V VETERINARSKI MEDICINI
Fertility:
Plodnost
Sheep from 1 month of age: injection of a single dose of 1 ml.
Osnovno cepljenje: Ovce od starosti 1 meseca: enkratni odmerek po 1 ml
Cattle from 6 weeks of age: injection of two doses of 1 ml, administered with an interval of approximately 3 weeks.
Osnovno cepljenje: Govedo od 6 mesecev starosti: dva odmerka po 1 ml v razmiku približno 3 tednov.
NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER AND OF THE MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE, IF DIFFERENT
Bovilis BTV8suspenzija za injiciranje za govedo in ovce IME IN NASLOV IMETNIKA DOVOLJENJA ZA PROMET Z ZDRAVILOM TER IMETNIKA DOVOLJENJA ZA IZDELAVO ZDRAVILA, ODGOVORNEGA ZA SPROSTITEV SERIJE, ČE STA RAZLIČNA
To stimulate active immunity in sheep from 1 month of age against bluetongue virus serotype 8 to prevent viraemia*.
Ovce Vzbujanje aktivne imunosti proti serotipu 8 virusa bolezni modrikastega jezika pri ovcah od starosti 1
Subcutaneous use.
Subkutana uporaba Ovce
Date of last renewal:
DATUM ZADNJE ODOBRITVE NAVODIL ZA UPORABO
Pregnancy and lactation: The vaccine can be used during pregnancy and lactation.
LLahko se uporablja v obdobju brejosti in laktacije.
4.11 Withdrawal period(s)
6.3 Rok uporabnosti
Contraindications relating to children less than 3 years of age and breastfeeding women were not included due to the lack of adequate data to support such contraindications.
Kontraindikacije, ki se nanašajo na otroke, mlajše od 3 let, in doječe matere, niso bile vključene zaradi pomanjkanja ustreznih podatkov za podporo takim kontraindikacijam.
Overall summary of the scientific evaluation by the CHMP
Splošni povzetek znanstvenega vrednotenja odbora CHMP
Also patients with severe renal impairment may require a lower initial dose, with subsequent adjustments.
Tudi pri bolnikih s hudo ledvično okvaro je morda potreben manjši začetni odmerek z naknadnimi prilagoditvami.
Due to the divergent national decisions taken by Member States concerning the authorisation of the above-mentioned product (and its associated names), the European Commission (EC) notified the European Medicines Agency's Secretariat of an official referral under Article 30 of Directive 2001/83/EC in order to resolve the divergences amongst the nationally approved SmPCs and thus to harmonise its divergent SmPCs across the EU.
Zaradi razhajajočih se nacionalnih odločitev, ki so jih sprejele države članice v zvezi z odobritvijo zgoraj navedenega zdravila (in povezanih imen), je Evropska komisija obvestila sekretariat Evropske agencije za zdravila o uradni napotitvi v skladu s členom 30 Direktive 2001/83/ES z namenom razrešitve razhajanj med nacionalno odobrenimi povzetki glavnih značilnosti zdravila in uskladitve razhajajočih se informacij po vsej EU.
The contraindications in section 4.3 were also amended to include the wording related to the contraindication of cardiotoxic risk of haloperidol.
Spremenjene so bile tudi kontraindikacije v poglavju 4.3, da vključujejo tudi besedilo v zvezi s kontraindikacijo glede tveganja kardiotoksičnosti haloperidola.
Haldol Decanoate has been approved nationally in the EU with many differences in the wording of the summary of product characteristics (SmPC), in the various Member States.
Zdravilo Haldol Decanoate je bilo odobreno na nacionalni ravni v EU z veliko razlikami v besedilu povzetka glavnih značilnosti zdravila v posameznih državah članicah.
In patients with hepatic impairment, it is recommended to halve the initial dose, since haloperidol is extensively metabolised in the liver.
Pri bolnikih z jetrno okvaro je priporočljivo prepoloviti začetni odmerek, saj se haloperidol obsežno presnavlja v jetrih.
Annex II Scientific conclusions
Priloga II
Based on the review of all available data and the consultations with the Healthcare Professionals Organisations (HCPOs), the CHMP recommended the following revision and harmonisation of the product information for Haldol Decanoate and associated names.
Na podlagi pregleda vseh razpoložljivih podatkov in posvetovanj z organizacijami zdravstvenih delavcev je odbor CHMP priporočil naslednjo spremembo in uskladitev informacij o zdravilu za zdravilo Haldol Decanoate in povezana imena.
The active substance haloperidol is a potent central dopamine type 2 receptor antagonist, lacking antihistaminergic or anticholinergic activity at recommended doses, and exerts minimal alpha 1 adrenergic activity.
Zdravilna učinkovina haloperidol je močan antagonist osrednjega dopaminskega receptorja tipa 2, ki nima antihistaminergičnega ali antiholinergičnega delovanja v priporočenih odmerkih in ima minimalno adrenergično delovanje alfa 1.
Given that the maximum dose of oral haloperidol in the elderly is 5 mg/day and applying the conversion factor of 15, the maximum haloperidol decanoate dose must not be in excess of 75 mg/4wk in the elderly unless elderly patients have already received higher haloperidol (oral or decanoate) doses for long-standing schizophrenia with acceptable tolerability.
Glede na to da je največji odmerek peroralnega haloperidola pri starejših bolnikih 5 mg/dan, pri uporabi konverzijskega faktorja 15 največji odmerek haloperidoldekanoata pri starejših bolnikih ne sme biti večji od 75 mg/4 tedne, razen če so starejši bolniki že prejeli večje odmerke haloperidola (peroralno ali v obliki dekanoata) za dolgoletno shizofrenijo in so jih sprejemljivo prenašali.
However specific guidance on switching from other antipsychotics has not been proposed due to limited data.
Vendar zaradi pomanjkanja podatkov natančnejša navodila za prehod z drugih antipsihotikov niso bila predlagana.
The proposal for the posology wording in section 4.2 has been revised with regard to transition from oral haloperidol, continuation of treatment, and supplementation with non-decanoate haloperidol up to the maximum oral dose, in adults and the elderly.
Predlog besedila odmerjanja v poglavju 4.2 je bil spremenjen glede prehoda s peroralnega haloperidola, nadaljevanja zdravljenja in dodajanja haloperidola brez dekanoata do največjega peroralnega odmerka pri odraslih in starejših bolnikih.
Haldol Decanoate - an ester of haloperidol and decanoic acid, is a depot antipsychotic belonging to the butyrophenone group.
Zdravilo Haldol Decanoate, ki vsebuje ester haloperidola in dekanojsko kislino, je depo antipsihotik, ki spada v skupino butirofenonov.
The final indication agreed for Haldol decanoate is for the maintenance treatment of schizophrenia and schizoaffective disorder in adult patients currently stabilised with oral haloperidol.
Usklajena indikacija za zdravilo Haldol Decanoate je vzdrževalno zdravljenje shizofrenije in shizoafektivne motnje pri odraslih bolnikih, ki sta trenutno stabilizirani s peroralnim haloperidolom.
Based on clinical trial data, guideline recommendations and expert consultations by the marketing authorisation holder (MAH) and by the HCPOs, a conversion factor of 10 to 15 is supported when switching from oral haloperidol to the longacting injectable (LAI) Haldol Decanoate.
Na podlagi podatkov iz kliničnih preskušanj in priporočil iz smernic ter posvetovanj s strokovnjaki, opravljenih pri imetniku dovoljenja za promet z zdravilom in organizacijah zdravstvenih delavcev, obstaja podpora za konverzijski faktor 10 do 15 pri prehodu s peroralnega haloperidola na zdravilo Haldol Decanoate z dolgotrajnim delovanjem za injiciranje.
As Haldol Decanoate is an injectable long-acting depot formulation recommended to be used every 4 weeks, in order to avoid medication errors in which either haloperidol injectable or haloperidol decanoate are administered in error, the MAH has committed to conduct further post-marketing safety analysis after completion of the Art 30 referral, while assessing the need for changing the name of the medicinal product thereafter.
Da bi preprečili napake pri zdravljenju zaradi nenamernega dajanja haloperidola za injiciranje ali haloperidoldekanoata v povezavi s priporočilom, da se zdravilo Haldol Decanoate v depo formulaciji za injiciranje z dolgotrajnim delovanjem daje vsake 4 tedne, se je imetnik dovoljenja za promet zavezal, da po končani napotitvi v skladu s členom 30 izvede dodatno analizo varnosti po dajanju zdravila na trg p in oceni potrebo po spremembi imena zdravila.
After intramuscular injection (IM), Haldol Decanoate is gradually released from muscle tissue and hydrolysed slowly into free haloperidol, which enters the systemic circulation.
postopoma sprosti iz mišičnega tkiva in počasi hidrolizira v prosti haloperidol, ki vstopi v krvni obtok.
A critical evaluation of the MAH's proposed harmonised SmPC is discussed below.
V nadaljevanju je obravnavana kritična ocena usklajenega povzetka glavnih značilnosti zdravila, ki ga je predlagal imetnik dovoljenja za promet z zdravilom.
Patients were followed up on average for 3.8 years.
Bolnike so spremljali povprečno 3,8 let.
It is given independent of meals and preferably at the same time each day.
Daje se neodvisno od obrokov, po možnosti vsak dan ob istem času.
These side effects usually pass after a few days or weeks of treatment.
Učinka običajno izzvenita v nekaj dneh ali tednih zdravljenja.
The European Commission granted a marketing authorisation valid throughout the European Union for Victoza on 30 June 2009.
Evropska komisija je dovoljenje za promet z zdravilom Victoza, veljavno po vsej Evropski uniji, izdala 30. junija 2009.
What measures are being taken to ensure the safe and effective use of Victoza?
Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Victoza?
Cardiovascular events occurred in 13% (608 out of 4668) of patients taking Victoza compared with 14.9% (694 out of 4672) of patients taking placebo.
Do srčnožilnih dogodkov je prišlo pri 13 % (608 od 4668) bolnikov, ki so prejemali zdravilo Victoza, v primerjavi s 14,9 % (694 od 4672) bolnikov, zdravljenih s placebom.
The full EPAR for Victoza can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Victoza je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
This is a summary of the European public assessment report (EPAR) for Victoza.
To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Victoza.
The main measure of effectiveness was the occurrence of one of three major cardiovascular events: stroke, heart attack or death caused by cardiovascular disease.
Glavno merilo učinkovitosti je bil pojav enega od treh glavnih srčnožilnih dogodkov: možganske kapi, srčnega napada ali smrti zaradi srčnožilne bolezni.
This means that it acts in the same way as incretins (hormones produced in the gut) by increasing the amount of insulin released by the pancreas in response to food.
To pomeni, da deluje na enak način kot inkretini (hormoni, proizvedeni v črevesju), in sicer s povečevanjem količine insulina, ki ga sprošča trebušna slinavka ob odzivu na hrano.
The study involved 9,340 patients with type 2 diabetes who already had cardiovascular disease (such as angina, heart attack or stroke).
V tej študiji je sodelovalo 9 340 bolnikov s sladkorno boleznijo tipa 2, ki so že imeli srčnožilne bolezni (kot je angina pektoris, srčni napad ali kap).
Other information about Victoza
Druge informacije o zdravilu Victoza
Victoza was compared with placebo and all patients also received standard care.
Zdravilo Victoza so primerjali s placebom in vsi bolniki so prejemali standardno oskrbo.
• on its own when use of metformin (another medicine for type 2 diabetes) is not recommended;
• samostojno, če uporaba metformina (drugega zdravila za zdravljenje sladkorne bolezni tipa 2) ni priporočljivo;
This compared with a reduction of 0.5 percentage points with glimepiride.
To je primerljivo z zmanjšanjem za 0,5 odstotne točke ob uporabi glimepirida.
The European Medicines Agency decided that Victoza's benefits are greater than its risks and recommended that it be given marketing authorisation.
Evropska agencija za zdravila je zaključila, da so koristi zdravila Victoza večje od z njim povezanih tveganj, in priporočila, da se zanj izda dovoljenje za promet.
Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Victoza have been included in the summary of product characteristics and the package leaflet.
Priporočila in varnostni ukrepi, ki jih morajo za varno in učinkovito uporabo zdravila Victoza upoštevati zdravstveni delavci in bolniki, so vključeni v povzetek glavnih značilnosti zdravila in navodilo za njegovo uporabo.
HbA1c gives an indication of how well the blood glucose is controlled.
HbA1c kaže, kako dobro je uravnana glukoza v krvi.
In some patients, the dose can be further increased to 1.8 mg one week later to achieve better control of blood glucose.
Pri nekaterih bolnikih se lahko odmerek po enem tednu dodatno poveča na 1,8 mg, da se doseže boljši nadzor nad ravnmi glukoze v krvi.
What is Victoza and what is it used for?
Kaj je zdravilo Victoza in za kaj se uporablja?
It is not intended to provide practical advice on how to use Victoza.
Povzetek ni namenjen zagotavljanju praktičnih nasvetov o njegovi uporabi.
In these studies, the main measure of effectiveness was the reduction in the amount of a substance in the blood called glycosylated haemoglobin (HbA1c) after six months or one year of treatment.
V teh študijah je bilo glavno merilo učinkovitosti zmanjšanje količine snovi v krvi, imenovane glikirani hemoglobin (HbA1c), po šestih mesecih ali enem letu.
Type 2 diabetes is a disease in which the pancreas does not make enough insulin to control the level of glucose (sugar) in the blood or when the body is unable to use insulin effectively.
Sladkorna bolezen tipa 2 je bolezen, pri kateri trebušna slinavka ne proizvaja dovolj insulina za vzdrževanje primerne ravni glukoze (sladkorja) v krvi ali pri kateri telo insulina ne more učinkovito uporabiti.
This helps with the control of blood glucose levels.
To pomaga uravnavati ravni glukoze v krvi.
The most common side effects with Victoza (seen in more than 1 patient in 10) are nausea and diarrhoea.
Najpogostejša neželena učinka zdravila Victoza (opažena pri več kot 1 bolniku od 10) sta navzea in driska.
In addition to the above studies, Victoza was shown to be effective in reducing adverse cardiovascular (heart and blood vessels) effects.
Poleg navedenih študij se je zdravilo Victoza izkazalo za učinkovito pri zmanjšanju neželenih učinkov na srčnožilni sistem (sistem srca in krvnih žil).
• as an ‘add-on' to other diabetes medicines.
• kot dodatek pri zdravljenju z drugimi zdravili za zdravljenje sladkorne bolezni.
What benefits of Victoza have been shown in studies?
Kakšne koristi je zdravilo Victoza izkazalo v študijah?
What are the risks associated with Victoza?
Kakšna tveganja so povezana z zdravilom Victoza?
When Victoza is added to existing treatment containing metformin or a thiazolidinedione, the doses of these medicines do not have to be changed.
Kadar se zdravilo Victoza dodaja obstoječemu zdravljenju z metforminom ali tiazolidindionom, odmerkov teh zdravil ni treba spreminjati.
Why is Victoza approved?
Zakaj je bilo zdravilo Victoza odobreno?
Victoza is a solution for injection available in pre-filled pens (6 mg/ml).
Zdravilo Victoza je na voljo v obliki raztopine za injiciranje v napolnjenih peresnikih (6 mg/ml).
Victoza is used:
Zdravilo Victoza se uporablja:
For more information about treatment with Victoza, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Za več informacij o zdravljenju z zdravilom Victoza preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
Results from this study show that Victoza at a dose of 1.2 mg reduced HbA1c by 0.8 percentage points, whereas Victoza at a dose of 1.8 mg led to reductions of 1.1 percentage points.
Rezultati te študije kažejo, da je zdravilo Victoza v odmerku 1,2 mg zmanjšalo ravni HbA1c za 0,8 odstotne točke, medtem ko je v odmerku 1,8 mg povzročilo zmanjšanje za 1,1 odstotne točke.
For practical information about using Victoza, patients should read the package leaflet or contact their doctor or pharmacist.
Za praktične informacije o uporabi zdravila Victoza naj bolniki preberejo navodilo za uporabo ali se posvetujejo z zdravnikom ali farmacevtom.
Victoza was effective at controlling blood glucose in six main studies involving 4,155 adults with type 2 diabetes.
Zdravilo Victoza so proučevali v šestih glavnih študijah, v katere je bilo vključenih 4 155 odraslih s sladkorno boleznijo tipa 2.
For the full list of all side effects and restrictions with Victoza, see the package leaflet.
Za celoten seznam vseh neželenih učinkov in omejitev pri uporabi zdravila Victoza glejte navodilo za uporabo.
The active substance in Victoza, liraglutide, is an ‘incretin mimetic'.
Zdravilna učinkovina v zdravilu Victoza, liraglutid, je „mimetik inkretina“.
The triple therapies containing Victoza led to a reduction of between 1.3 and 1.5 percentage points compared with a reduction equal or less than 0.5 points without Victoza.
Zdravljenje s tremi zdravili, ki je vključevalo zdravilo Victoza, je povzročilo zmanjšanje za 1,3 do 1,5 odstotne točke, v primerjavi z zdravljenjem brez zdravila Victoza, pri katerem je bilo zmanjšanje enako ali manjše od 0,5 odstotne točke.
Victoza is a medicine used in addition to diet and exercise in adults who have type 2 diabetes.
Zdravilo Victoza se uporablja kot dodatek dieti in telesni vadbi pri odraslih s sladkorno boleznijo tipa 2.
Adding Victoza to treatment with basal insulin plus metformin reduced HbA1c by 0.7 percentage points, compared with 0.4 points when adding Victoza to insulin aspart.
Pri dodajanju zdravila Victoza kombinaciji bazalnega insulina in metformina so se ravni HbA1c zmanjšale za 0,7 odstotne točke v primerjavi z 0,4 odstotne točke pri dodajanju zdravila Victoza insulinu aspartu.
Victoza is given by the patient once a day by injection under the skin in the abdomen, thigh or upper arm.
Bolnik si ga injicira v podkožje na trebuhu, stegnu ali nadlakti enkrat na dan.
Combinations containing Victoza were more effective at controlling blood glucose than combinations without the medicine.
Kombinacije, ki so vključevale zdravilo Victoza, so bile učinkovitejše pri uravnavanju glukoze v krvi kot kombinacije brez tega zdravila.